Massachusetts Financial Services CO Argenx Se Transaction History

Massachusetts Financial Services CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$356.95 - $413.29 $59.3 Million - $68.7 Million	-166,119 Reduced 28.08%	425,547 $168 Million
Q4 2023 Feb 08, 2024	BUY	$338.91 - $506.01 $3.42 Million - $5.1 Million	10,080 Added 1.73%	591,666 $225 Million
Q3 2023 Nov 08, 2023	BUY	$369.35 - $548.43 $166 Million - $246 Million	449,151 Added 339.15%	581,586 $286 Million
Q2 2023 Aug 09, 2023	BUY	$360.14 - $422.58 $47.7 Million - $56 Million	132,435 New	132,435 $51.6 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.